GREENLAND MINES LTD Deferred Taxes, Business Combination, Valuation Allowance, Available to Reduce Intangible Assets
GREENLAND MINES LTD (GRML) had Deferred Taxes, Business Combination, Valuation Allowance, Available to Reduce Intangible Assets of $1.92 million as of 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Notes › Income Taxes
us-gaap:DeferredTaxesBusinessCombinationValuationAllowanceAvailableToReduceIntangibleAssets · last filed 2025-03-31
- 2024-12-31: Deferred Taxes, Business Combination, Valuation Allowance, Available to Reduce Intangible Assets $1.92M.
- 2023-12-31: Deferred Taxes, Business Combination, Valuation Allowance, Available to Reduce Intangible Assets $1.92M; Deferred Taxes, Business Combination, Valuation Allowance, Available to Reduce Intangible Assets as first filed $308.26K.
- 2022-12-31: Deferred Taxes, Business Combination, Valuation Allowance, Available to Reduce Intangible Assets $112.14K.
| Period end | Deferred Taxes, Business Combination, Valuation Allowance, Available to Reduce Intangible Assets | Deferred Taxes, Business Combination, Valuation Allowance, Available to Reduce Intangible Assets as first filed |
|---|---|---|
| 2024-12-31 | $1.92M 10-K · filed 2025-03-31 | |
| 2023-12-31 | $1.92M 10-K · filed 2025-03-31 | $308.26K 10-K · filed 2024-04-17 |
| 2022-12-31 | $112.14K 10-K · filed 2024-04-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |